Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ANV 419

Next Previous
X
Search
Drug Profile

ANV 419

Alternative Names: ANV-419

Latest Information Update: 15 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anaveon
  • Class Adjuvants; Antibodies; Antineoplastics; Immunotherapies; Interleukins
  • Mechanism of Action Immunostimulants; Interleukin 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Solid tumours
  • Phase I Multiple myeloma

Most Recent Events

  • 15 Oct 2024 Vall d'Hebron Institute of Oncology plans a phase II trial for Malignant melanoma, Cervical cancer, Non small cell lung cancer (Metastatic disease, Unresectable/Inoperable) in Spain (IV, Infusion) in October 2024 (NCT06630611)
  • 01 Aug 2024 Anaveon AG completes a phase-I/II clinical trials in Malignant melanoma (Inoperable/Unresectable, Metastatic disease, Combination therapy) in USA, France, Germany, Italy, Spain (IV) (NCT05578872)
  • 01 Aug 2024 Anaveon AG completes a phase-I/II clinical trials in Malignant melanoma (Inoperable/Unresectable, Metastatic disease, Monotherapy) in USA, France, Germany, Italy, Spain (IV) (NCT05578872)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top